BioCentury
ARTICLE | Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

October 19, 2018 6:34 PM UTC

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of the product.

The company said it believes the inflammation is isolated to the single lot based on a preliminary toxicity analysis, and if confirmed by a series of non-human studies, Apellis will resume dosing in the Phase III program by year end...

BCIQ Company Profiles

Apellis Pharmaceuticals Inc.

BCIQ Target Profiles

Complement 3 (C3)